Skip to main content
OpenTrials
Completed

NCT Number: NCT02757430

EnSite Precision™ 2.0 Registry

The objective of this registry is to assess and characterize the use and performance of the EnSite Precision™ Cardiac Mapping System and the EnSite Precision™ Software V2.0 in a variety of electrophysiological (EP) procedures and clinical settings. This registry will assess the clinical performance of the system in a controlled, real-world environment after commercial release.

Up to 500 subjects will be enrolled in up to 50 sites worldwide.

Data will be collected at enrollment/baseline, procedure and pre-discharge. There is no long-term follow-up required for this registry.

The anticipated registry enrollment is about 6-7 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale Cardinal Massaia di Asti

Asti, 14100, Italy

About this study

The use of the EnSite Precision™ Cardiac Mapping System will be assessed by collecting feedback from physicians/operators through specific questions.

The performance of the EnSite Precision™ Cardiac Mapping System will be assessed by collecting procedure data and adverse events.

A detailed Data Management Plan will be established to ensure consistency of the data. This document will include procedures used for data review, database cleaning, and issuing and resolving data queries. If appropriate, the Data Management Plan may be updated throughout the registry duration. All revisions will be tracked and document controlled.

Case Report Form data will be captured in a validated electronic database management system hosted by St. Jude Medical.

Centralized monitoring will occur through routine internal data review. This monitoring is designed to identify missing and inconsistent data, data outliers, and potential protocol deviations that may be indicative of site non-compliance. On-site monitoring may occur at the discretion of the sponsor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients indicated for a cardiac EP study and ablation procedure using a 3D mapping system
  • Over 18 years of age
  • Ability to provide informed consent for registry participation and be willing and able to comply with the protocol described evaluations

Exclusion criteria

  • Contraindication to anticoagulation
  • Presence of thrombus
  • Implanted with mechanical prosthetic heart valve
  • Recent (<3 months) myocardial Infarction or unstable angina or coronary artery by-pass
  • Pregnant or nursing
  • Individuals whose willingness to volunteer in a registry, in the judgment of investigator or public authorities, could be unduly influenced by lack of or loss of the autonomy due to immaturity, or mental disability, or adverse personal circumstances, or hierarchical influence

Treatment and study plan

Cardiac Ablation

Procedure

Primary outcomes

  1. Assessment of the EnSite Precision™ Software V2.0 in Terms of Geometry Accuracy

    Time frame: during procedure

    summarizing the count and percentage of patients with accurate geometry

  2. Mapping Time Associated With (re-)Mapping One or Multiple Arrhythmias in a Single Subject With a Variety of Catheters

    Time frame: during procedure

    mapping time will be summarized (using mean and standard deviation across arrhythmia types, and for each type of arrhythmia as appropriate) for the following modules: Manual AutoMap™ TurboMap™

  3. Mapping Time Associated With (re-)Mapping One or Multiple Arrhythmias in a Single Subject With a Variety of Catheters With Manual Mapping

    Time frame: during procedure

    mapping time will be summarized (using mean and standard deviation across arrhythmia types, and for each type of arrhythmia as appropriate) for the following modules: Manual

  4. Mapping Time Associated With (re-)Mapping One or Multiple Arrhythmias in a Single Subject With a Variety of Catheters With AutoMap Module Mapping

    Time frame: during procedure

    mapping time will be summarized (using mean and standard deviation across arrhythmia types, and for each type of arrhythmia as appropriate) for the following modules: AutoMap module

  5. Mapping Time Associated With (re-)Mapping One or Multiple Arrhythmias in a Single Subject With a Variety of Catheters With TurboMap Module Mapping

    Time frame: during procedure

    mapping time will be summarized (using mean and standard deviation across arrhythmia types, and for each type of arrhythmia as appropriate) for the following modules: TurboMap module

  6. Point Density Associated With (re-)Mapping One or Multiple Arrhythmias in a Single Subject With a Variety of Catheters

    Time frame: during procedure

    mapping points collected and used will be summarized (using mean and standard deviation across arrhythmia types, and for each type of arrhythmia as appropriate)

  7. Assessment of the EnSite Precision™ Software V2.0 in Terms of System Stability

    Time frame: during procedure

    summarizing the count and percentage of patients with overall system stability

  8. Assessment of the EnSite Precision™ Software V2.0 in Terms of Unrecoverable Shifts

    Time frame: during procedure

    summarizing the count and percentage of patients with unrecoverable shifts

Secondary outcomes

  1. EnSite Precision™ Cardiac Mapping System Assessment

    Time frame: during procedure

    Count and percentage of subjects in whom the mapping system was reported to be excellent, very good, good, poor and N/A

  2. EnSite Precision™ Cardiac Mapping System Assessment

    Time frame: during procedure

    Overall procedure time summarized using mean and standard deviation

  3. Clinical Utility and Ease of Use of the Automated Radiofrequency Marker Placement

    Time frame: during procedure

    Count and percentage of subjects where the AutoMark feature assisted in identifying gaps in lesion lines

  4. Clinical Utility and Ease of Use of the Automated Radiofrequency Marker Placement

    Time frame: during procedure

    Count and percentage of subjects where the AutoMark feature was easy to use

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

EnSite Precision™ Cardiac Mapping System and EnSite Precision™ Software v2.0 Observational Registry

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 2, 2016
Registry last updated
May 6, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.